We work on cancer prevention and immunotherapy using tumour-targeted replicating oncolytic viruses, in particular focusing on replicating adenovirus and vaccinia virus.
Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nature communications (2017) 8(1): 1395. PMID: 29123084
A Vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer. Clin Cancer Res (2015) 21(2): 405-16. PMID: 25416195
A novel therapeutic regime to eradicate established solid tumors with an effective induction of tumor-specific immunity. Clin Cancer Res (2012) 18(24):6679-89. PMID: 23091113
CEACAM6 attenuates adenovirus infection by antagonizing viral trafficking in cancer cells. J Clin Invest (2009) 119(6):1604-15. PMID: 19411761
E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumour models. Nature Biotechnology (2003) 21(11): 1328-35. PMID: 14555956
The major research interest in my group is developing new cancer immunotherapy agents or/and approaches through comprehensive investigations into the interaction of oncolytic viruses, tumour cells, tumour microenvironment and host immune responses.
Our four main research areas of interests are:
The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature. Inman GJ, Wang J, Nagano A et al. Nat Commun (2018) 9(2) 3667
Characterization of an N-Terminal Non-Core Domain of RAG1 Gene Disrupted Syrian Hamster Model Generated by CRISPR Cas9. Miao J, Ying B, Li R et al. Viruses (2018) 10(2)
Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer. Marelli G, Howells A, Lemoine NR et al. Frontiers in Immunology (2018) 9(1) 866-866
IW-Scoring: an Integrative Weighted Scoring framework for annotating and prioritising genetic variations in the noncoding genome. Nucleic Acids Research WANG Y Nucleic Acids Research (2018) (1)
Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Wang P, Li X, Wang J et al. Nat Commun (2018) 9(2) 203
Production of Genetically Engineered Golden Syrian Hamsters by Pronuclear Injection of the CRISPR/Cas9 Complex. Li R, Miao J, Fan Z et al. J Vis Exp (2018) (2)
Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells. Delaunay T, Violland M, Boisgerault N et al. Oncoimmunology (2017) 7(1) e1407897-e1407897
CRISPR-Cas9 HDR system enhances AQP1 gene expression. Wang Z, Wang Y, Wang S et al. Oncotarget (2017) 8(2) 111683-111696
The development of a monolith-based purification process for Orthopoxvirus vaccinia virus Lister strain. Vincent D, Kramberger P, Hudej R et al. J Chromatogr A (2017) 1524(2) 87-100
Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Wang P, Li X, Wang J et al. Nat Commun (2017) 8(1) 1395-1395
Clinical Research Fellows
Dr Lewis Stephen
Ms Zuoyi Zhao, Mr Christian Jacobus Bouwens, Ms Carmela Di Gioia, Ms Elisa Heyrman
Visiting Research Fellows
Ms Lijuan Chen, Ms Yafeng Wang
I qualified in medicine and obtained my PhD in 1997. From 1999 to 2005, I undertook postdoctoral research in molecular biology of cancer as well as cancer viral and genetic therapy at the MRC Toxicology Unit in Leicester University and the Cancer Research UK Molecular Oncology Unit based at Imperial College London.
I joined the Barts Cancer Institute (formerly Institute of Cancer) on 1st July 2005 as a Lecturer. I was promoted to a senior Lecturer and subsequently Reader in Molecular Oncology in 2007 and 2011, respectively, and became Professor of Cancer Cell and Gene Therapy in 2015.
I established the first Sino-British Research Centre for Molecular Oncology with Prof Nick Lemoine in 2006. The Centre was a joint venture entity between Queen Mary University of London and Zhengzhou University. The Centre was elected as a National Centre for International Research in Cell and Gene Therapy by the Ministry of Science and Technology of China in 2014. I have been appointed as the Director of the Centre since then.
I have been working in cancer virotherapy since 2001 with a substantial track record of publications in prestigious scientific journals such as “Nature Biotechnology”, “The Journal of Clinical Investigation (JCI)”, “Gut”, and “Nature Communications”, etc.
My long-term research aim is to develop more effective cancer cell and gene therapies based on the genetically engineered oncolytic virus platform, for prevention, diagnosis and treatment of human cancer, and advance them into clinical testing.